Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes’ Attune total knee arthroplasty system is experiencing an “unusually high” rate of early failure related to its tibial components, according to a new study.
A Leading National Law Firm
Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes’ Attune total knee arthroplasty system is experiencing an “unusually high” rate of early failure related to its tibial components, according to a new study.
